Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
UK approves Merck's therapy for rare lung condition
07:48am, Tuesday, 31'st Dec 2024
UK's Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck's therapy to treat a rare lung condition called pulmonary arterial hypertension.
2 High-Yield Dividend Stocks to Buy Early in 2025
07:45am, Tuesday, 31'st Dec 2024
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:56pm, Monday, 30'th Dec 2024
The latest trading day saw Merck (MRK) settling at $98.37, representing a -1.33% change from its previous close.
US Large Cap Dividend Stocks Should Roll in 2025: Our 4 Favorite Picks
11:14am, Monday, 30'th Dec 2024
Large-capitalization dividend stocks are a favorite among investors for a good reason.
2 Reasons to Sell Merck Stock and 1 Reason to Buy
09:45am, Thursday, 26'th Dec 2024
There is plenty to like about Merck (MRK -0.25%). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda.
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:51pm, Tuesday, 24'th Dec 2024
Merck (MRK) closed the most recent trading day at $99.45, moving +0.08% from the previous trading session.
Merck to discontinue drug for bacterial infection
06:43pm, Monday, 23'rd Dec 2024
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday.
Merck: A Low-Hanging Fruit To Pick
09:00am, Monday, 23'rd Dec 2024
Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, is now a $258 billion (by market cap) healthcare behemoth. The US is the co
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
02:51pm, Sunday, 22'nd Dec 2024
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Is Merck the Next Big Weight-Loss Stock?
06:45am, Sunday, 22'nd Dec 2024
Watch out, Eli Lilly and Novo Nordisk. Merck (MRK -1.48%) is hungrily looking to take a bite out of the weight-loss drugs market.
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
02:05pm, Friday, 20'th Dec 2024
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
10:21am, Friday, 20'th Dec 2024
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:06am, Friday, 20'th Dec 2024
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
07:45am, Friday, 20'th Dec 2024
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many divid
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
06:45am, Friday, 20'th Dec 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel invest
